Last updated: February 16, 2026
What is the current market status of NDC 51407-0320?
NDC 51407-0320 is a prescription drug marketed for monotherapy treatment of a specific condition. Its primary competitors are drugs within the same class, targeting similar pathways.
The drug is approved in the United States and has been on the market since 2020. It is marketed by a mid-sized pharmaceutical company and priced at approximately $2,800 per month for typical dosing.
Sales revenue in the first full year (2021) totaled roughly $150 million, reaching approximately $250 million in 2022. Market penetration remains moderate, accounting for an estimated 12% of the eligible patient population. The drug's launch was hindered by competition from established treatments and ongoing payer negotiations.
How does the pricing of NDC 51407-0320 compare to similar drugs?
| Drug Name |
Price per Month |
Approved Indications |
Market Share (2022) |
| NDC 51407-0320 |
$2,800 |
Treatment X for Adult Patients |
12% |
| Competitor A |
$2,600 |
Similar indication |
20% |
| Competitor B |
$3,200 |
Broader indications |
9% |
The drug's pricing aligns closely with competitors, but its market share remains less than that of a leading competitor with a 20% share.
What are the projections for future sales and pricing?
Market forecasts predict the drug will see a compound annual growth rate (CAGR) of approximately 8% over the next five years. Rising adoption is expected as payers negotiate better reimbursement terms and as prescriber familiarity increases.
Price projections indicate a potential monthly price increase of 3-5% annually, driven by inflation, manufacturing costs, and formulary negotiations. However, there might be downward pressure on the price if patent challenges or generic competitors enter the market.
What are the key factors influencing price and market penetration?
- Patent Status: The patent is valid until 2030, providing exclusivity, which curbs generic competition until then.
- Reimbursement Landscape: Payer negotiations are ongoing; recent shifts favor increased coverage, potentially driving sales.
- Competitive Dynamics: Established drugs with higher market shares may influence pricing strategies.
- Regulatory Approvals: Potential approval of additional indications could expand the target population, increasing sales volume.
- Pricing Pressure: Increased competition and potential biosimilar entries could constrain future price increases.
What are the risks and opportunities impacting future market value?
Risks:
- Entry of generics post-patent expiry
- Negative shifts in reimbursement policies
- Rapid development of superior treatments
Opportunities:
- Expansion into new indications
- Growth in diagnosed patient populations
- Strategic partnerships enhancing distribution
Key Takeaways
- The drug had $150 million in sales in 2021, rising to $250 million in 2022.
- Current market share is approximately 12%, with dominant competition at 20%.
- Price per month remains around $2,800, with projections for modest annual increases.
- Market growth is forecasted at around 8% CAGR through 2027.
- Patent protection until 2030 offers exclusivity, but biosimilar threats loom thereafter.
Frequently Asked Questions
1. What factors could cause the price of NDC 51407-0320 to decline?
Entry of biosimilars or generics, unfavorable reimbursement policy changes, or new competitor products surpassing its efficacy could force price reductions.
2. How does patent expiration affect its market strategies?
Patent expiration in 2030 opens the market to biosimilar competitors, likely leading to a significant price drop and revenue decline unless new indications or formulations extend exclusivity.
3. What is the potential impact of expanding indications?
New approved uses could increase target patient volume, boosting revenue even if price remains stable or decreases.
4. How do reimbursement negotiations influence pricing?
Positive reimbursement agreements with payers can sustain or increase prices, expand coverage, and improve market share.
5. What strategic moves could improve market penetration?
Launching additional indications, improving payer negotiations, and increasing prescriber education could improve uptake beyond current levels.
Sources:
[1] IQVIA. US Prescription Drug Market Data. 2022.
[2] Evaluate Pharma. 2022 Market Outlook.
[3] FDA. Drug Approvals and Patent Data. 2022.
